Cytek Biosciences Inc. Common Stock (CTKB)

About CTKB

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approac…

Sector

Industrials

Industry

Biotechnology: Laboratory Analytical Instruments

Employees

682

Website

cytekbio.com

Fundamentals

1-day range

$4.12$4.24

Market cap

$537.23M

P/E (trailing)

—

P/E (forward)

60.00

EPS (trailing)

$-0.63

Dividend yield

—

Beta

1.21

Avg. volume

1.40M

Forecasts

4 analyst ratings

Cytek Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CTKB

  Cytek Biosciences Inc. Common Stock

  $4.69

  ▲ 1.41%
  Market cap $537.23MP/E —
  $3.28$6.18
• PACB

  Pacific Biosciences of California Inc. Common Stock

  $1.4

  ▼ 10.00%
  Market cap $361.85MP/E —
  $1.07$2.73
• QTRX

  Quanterix Corporation Common Stock

  $2.64

  ▼ 0.00%
  Market cap $180.42MP/E —
  $2.15$8.77
• SEER

  Seer Inc. Class A Common Stock

  $1.99

  ▼ 1.00%
  Market cap $120.41MP/E —
  $1.55$2.41
• NAUT

  Nautilus Biotechnology Inc. Common Stock

  $0.8828

  ▼ 2.35%
  Market cap $112.76MP/E —
  $0.62$4.31
• RPID

  Rapid Micro Biosystems Inc. Class A Common Stock

  $1.56

  ▼ 3.11%
  Market cap $96.03MP/E —
  $1.52$4.94
• CIRC

  Circle8 Group Inc. Common Stock

  $0.7246

  ▲ 2.34%
  Market cap $70.73MP/E —
  $0.4773$0.98

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Cytek Biosciences Says Jury Finds In Cytek’s Favor On Three Of Four Asserted Patent Claims; To Challenge Remaining Finding; Jury Awarded Past Damages Consisting Of $20M In Lost Profits And $36M In Royalties
  Benzinga · 8/21/2026
• Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/6/2026
• Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/6/2026
• Cytek Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/6/2026
• Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...
  Yahoo · 8/6/2026
• Cytek Biosciences Q2 Earnings Call Highlights
  Yahoo · 8/6/2026
• Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
  Yahoo · 8/5/2026
• Cytek Biosciences Reports Second Quarter 2026 Financial Results
  Yahoo · 8/5/2026

• Feuchtwang Ilan · August 10, 2026 · Grant

  127.1K
• Feuchtwang Ilan · August 10, 2026 · Grant

  241.4K
• Ming Yan · June 12, 2026 · Gift

  135.9K
• Vera Imper · June 10, 2026 · Option Exercise

  44.0K
• Vera Imper · June 10, 2026 · Grant

  18.3K
• Vera Imper · June 10, 2026 · Grant

  33.3K
• Jack Ball · June 10, 2026 · Option Exercise

  44.0K
• Michael Holder · June 10, 2026 · Option Exercise

  44.0K
• Michael Holder · June 10, 2026 · Grant

  18.3K
• Michael Holder · June 10, 2026 · Grant

  33.3K
• Richard Chin · June 10, 2026 · Grant

  18.3K
• Richard Chin · June 10, 2026 · Grant

  33.3K
• Deborah J. Neff · June 10, 2026 · Option Exercise

  44.0K
• Deborah J. Neff · June 10, 2026 · Grant

  18.3K
• Deborah J. Neff · June 10, 2026 · Grant

  33.3K

Institutional Ownership

March 31, 2026

Total shares held

81.71M

Total value held

$351.24M

Institutional holders

161